POZEN INC (POZN)
 
Quote Price $7.18
Price change for today in $ 0.33
Price change for today in % 4.82
Open Price $6.97
Previous Close $6.85
Daily Range $6.80 - $7.19
52-Week Range $2.15 - $8.12
Volume 383,096
 
 
Brokerage Analyst Recommendations 
4 Brokerage Firms Covering POZN
 
   
Strong Buy
1 		Buy
1 		Hold
2		 Sell
0		 Strong Sell
0
Average Broker Recommendation (ABR):2.25 
 
Description
Pozen Inc. is pharmaceutical development company committed to building a portfolio of products with significant commercial potential in select therapeutic areas. Its initial area of focus is migraine, where the company have built a portfolio of four product candidates through a combination of innovation and in-licensing. Its lead product candidate is MT 100, which the company is developing as an oral first-line therapy for the treatment of migraine.
 
1414 RALEIGH ROAD SUITE 400
CHAPEL HILL, NC
27517, USA
Phone: 919-913-1030
Fax: 919-913-1039
Web: http://www.pozen.com
Email: nvestor@pozen.com		 Industry:MED-DRUGS
Sector: Medical
Fiscal Year End:December
Last Reported Quarter:03/31/12
Next EPS Date:07/26/12
 
Capital Structure Solvency and Cash Flow
No comments yet. Be the first
make a comment about Capital Structure Solvency and Cash Flow
 
Governance Social Responsibility and Employee Relations
No comments yet. Be the first
make a comment about Governance Social Responsibility and Employee Relations
 
Acquisitions Divestitures and Joint Ventures
No comments yet. Be the first
make a comment about Acquisitions Divestitures and Joint Ventures
 
Recent and Upcoming Events
Jun 21, 2011 01:06 Pozen Names Martin Nicklasson to the Board of Directors
Jun 18, 2011 10:58 The 5 Companies in the Pharmaceuticals Industry With the Lowest P/E Ratio (BSPM, DEPO, POZN, LLY, FRX)
Jun 17, 2011 05:42 POZEN Inc names Dr Martin Nicklasson to board
Jun 16, 2011 12:01 POZEN Announces Election of Dr. Martin Nicklasson to the Board of Directors
Jun 15, 2011 07:30 POZEN to Present at The UBS Specialty Pharmaceuticals Conference
Jun 10, 2011 08:11 Pozen focuses on advancing products
Jun 09, 2011 08:03 Depomed has the Highest Return on Equity in the Pharmaceuticals Industry (DEPO, POZN, LLY, AZN, MDCO)
Jun 09, 2011 07:30 POZEN to Present at the 2011 Wells Fargo Securities Healthcare Conference
Jun 08, 2011 07:56 Depomed has a Relatively High Earnings Yield in the Pharmaceuticals Industry (DEPO, POZN, LLY, FRX, PFE)
May 25, 2011 07:30 POZEN Ranked as Second Most Efficient Pharma Company by SmarTrend
May 24, 2011 07:38 Depomed has a Relatively High Earnings Yield in the Pharmaceuticals Industry (DEPO, FRX, POZN, LLY, PFE)
May 24, 2011 07:30 POZEN to Present at the Jefferies 2011 Global Life Sciences Conference
May 14, 2011 10:07 Losses Projected for Pozen Following Last Year's Profits (POZN)
May 12, 2011 07:36 Relatively High Company Efficiency Detected in Shares of Columbia Laboratories in the Pharmaceuticals Industry (CBRX, POZN, DEPO, VPHM, PTIE)
May 05, 2011 07:30 POZEN Reports First Quarter 2011 Results

 
Major Risks
No comments yet. Be the first
make a comment about Major Risks
 


Created by: WikiMigrationBot. Last Modification: Thursday 03 of June, 2010 08:41:46 CDT by WikiMigrationBot.